Teva Pharmaceutical Industries Limited or Taro Pharmaceutical Industries Ltd.: Who Leads in Yearly Revenue?

Teva vs. Taro: A Decade of Revenue Rivalry

__timestampTaro Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 201475928500020272000000
Thursday, January 1, 201586294400019652000000
Friday, January 1, 201695075100021903000000
Sunday, January 1, 201787938700022385000000
Monday, January 1, 201866191300018854000000
Tuesday, January 1, 201966989300016887000000
Wednesday, January 1, 202064476900016658000000
Friday, January 1, 202154897000015878000000
Saturday, January 1, 202256134700014925000000
Sunday, January 1, 202357295200015846000000
Monday, January 1, 202462918200016544000000
Loading chart...

In pursuit of knowledge

A Tale of Two Pharmaceutical Giants: Teva vs. Taro

In the competitive world of pharmaceuticals, Teva Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. have been key players. Over the past decade, Teva has consistently outpaced Taro in annual revenue, boasting figures that are nearly 25 times higher. In 2016, Teva reached its peak with a revenue of approximately $21.9 billion, while Taro's highest was around $950 million in the same year. However, both companies have faced challenges, with Teva's revenue declining by about 32% from 2016 to 2022, and Taro experiencing a 41% drop in the same period. Despite these setbacks, Teva remains a dominant force, while Taro continues to hold its ground in a niche market. As of 2023, Teva's revenue shows signs of stabilization, while Taro's figures suggest a potential rebound. The future remains uncertain, but both companies are poised to adapt and innovate in the ever-evolving pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025